Sqy Therapeutics
Develops antisense oligonucleotide drug candidates for people with genetic diseases, particularly Duchenne muscular dystrophy
Highlights
- New on EvolcAdded 2026-10-30
About Sqy Therapeutics
SQY Therapeutics is a biotechnology company developing antisense oligonucleotide medicines for genetic diseases, with a focus on Duchenne muscular dystrophy. Its candidate SQY51 targets exon 51 of dystrophin pre-mRNA to restore a functional reading frame through exon skipping.
SQY51 has entered clinical testing in the AVANCE 1 trial. The company is headquartered in Guyancourt, France, and was founded in 2015.
Product: Researches and develops antisense oligonucleotide drug candidates, including SQY51 for Duchenne muscular dystrophy.
Jobs at Sqy Therapeutics
No open positions listed right now.
More biotech & pharma companies
Stanipharm
CDMO services for life-science companies developing and manufacturing pharmaceutical ingredients and nanoformulationsNew on EvolcStem Genomics
Genomic stability and cell identity testing for research and biotech labs working on human stem cellsNew on EvolcStemcell Technologies
Cell culture products, instruments and research services for life science researchers worldwideNew on EvolcSubstipharm
Develops and supplies medicines and vaccines for pharmaceutical partners and patients worldwideNew on EvolcTedis
Pharmaceutical wholesale distributor linking laboratories with pharmacies and hospitals in France and export markets in Africa and AsiaNew on EvolcSalary transparentThea Open Innovation
Ophthalmology innovation partnerships and investment for startups, researchers and companies developing eye-care treatmentsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Elementor
- Google reCAPTCHA
- Matomo
- PHP
- WordPress
- jQuery